表紙
市場調査レポート

世界の医薬品リパーパシング市場

Global Markets for Drug Repurposing

発行 BCC Research 商品コード 347802
出版日 ページ情報 英文 103 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
世界の医薬品リパーパシング市場 Global Markets for Drug Repurposing
出版日: 2016年01月01日 ページ情報: 英文 103 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の医薬品リパーパシング市場は、2015年の244億米ドルから2020年には313億米ドルとなり、2015〜2020年のCAGRは5.1%となると見込まれています。

レポートでは、医薬品リパーパシング市場について調査し、市場の概要と2020年までの予測、リパーパシングのための新たなツールと技術の概要、および主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 概要

  • 定義
  • 医薬品
  • 医薬品の分類
  • 医薬品開発プロセス
  • 医薬品リパーパシング
  • リパーパシング方法
  • 応用分野
  • 利点と限界

第4章 法規制側面

  • リコール
  • 安全性に関する警告

第5章 動向

  • 原則的リパーパシング
  • 合併・買収
  • 現況
  • 医薬品リパーパシングの影響因子
    • 促進因子
    • 阻害因子
  • 市場の機会

第6章 市場分析

  • イントロダクション
  • 地域別市場
    • 収益
    • 市場シェア
  • 用途別市場
    • 市場概要
    • 収益
    • 市場シェア
    • 中枢神経系疾患
    • 心血管疾患
    • 腫瘍
    • 自己免疫疾患
    • 代謝性疾患その他
  • 使用別市場
  • 応用部位別市場分析

第7章 業界構造

  • 中枢神経系疾患
  • 自己免疫疾患
  • 腫瘍
  • 心血管疾患
  • 代謝性疾患
  • その他

第8章 用途別市場

第9章 企業プロファイル

第10章 付録:略語

図表

目次
Product Code: PHM175A

REPORT HIGHLIGHTS

The global market for drug repurposing will grow from nearly $24.4 billion in 2015 to nearly $31.3 billion by 2020, with a compound annual growth rate (CAGR) of 5.1% for the period of 2015-2020.

This report provides:

  • An overview of the global markets for drug re-purposing, (also known as re-positioning or re-profiling) referring to studies about a compound or a biologic agent that treats one condition and sees if that particular compound is safe and effective for treating other diseases.
  • Analyses of U.S. as well as international market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
  • A look at how human intervention and investigation early in the drug discovery process is helping in faster development of therapeutics.
  • Evaluation of drug-repurposing compared to traditional drug development where cost and the time for the drug to be available in the market is greatly reduced since the re-purposed drug has already passed a significant number of tests.
  • Coverage of how the discovery process for repurposing drugs has accelerated in recent years due to the emergence of new tools and technologies.
  • Profiles of major players in the industry.

SCOPE OF THE REPORT

This report provides a global overview of drug repurposing, also known as repositioning or reprofiling, including the techniques and applications in various therapies. The report deals with the global market for repurposed drugs in three main areas: market by application of repurposed drugs, by usage of repurposed drugs and by application site (i.e., whether they are used orally or intravenously). The application area is divided into types of disorders (i.e., repurposed drugs in central nervous disorders, cardiovascular disorders, oncology, metabolic, autoimmune and other disorders). Market by usage is analyzed on the basis that repurposed drugs are used alone in single therapy or used in combination with other drugs.

Excluded from this report are drugs that are not yet approved as repurposed drugs. BCC Research analyzes the market and its applications, regulatory environment, technologies involved, market projections and market shares. The market is mainly divided into theU.S.and the rest of the world (ROW).

Also included in the report are relevant patent analysis and comprehensive profiles of the leading companies in the drug repurposing market. The key players are Novartis AG, Abbott Healthcare, Pfizer Inc., Johnson & Johnson and Hoffmann-La Roche. Other significant players are the generic drug manufacturers such as Sandoz, Mylan Inc., and Teva Pharmaceuticals. The chapter on company profiles also includes even core drug repurposing companies such as SOM Biotech, Biovista Inc. and Sosei Group Ltd.

ANALYST'S CREDENTIALS

The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies inIndiaand in theU.S.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE REPORT
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION, 2013-2020 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • DEFINITIONS
    • DRUG
    • CHEMICAL DRUG
    • BIOLOGICAL DRUG
    • DRUG REPURPOSING
    • ACTIVE PHARMACEUTICAL INGREDIENT (API)
    • DRUG DEVELOPMENT
  • PHARMACEUTICAL DRUGS
  • CLASSIFICATION OF DRUGS
    • CHEMICAL OR SMALL MOLECULE DRUGS
    • BIOLOGIC DRUGS
      • TABLE 1 COMPARISON OF CHEMICALLY SYNTHESIZED DRUGS AND BIOLOGIC DRUGS
    • HISTORY OF PHARMACEUTICAL DRUGS
      • TABLE 2 EVOLUTION OF DRUG PRODUCTS
  • DRUG DEVELOPMENT PROCESS
    • TARGET SELECTION/IDENTIFICATION
    • TECHNIQUES FOR TARGET IDENTIFICATION
    • TARGET VALIDATION
    • DRUG DISCOVERY/LEAD DISCOVERY
    • INITIAL SAFETY TESTS
    • LEAD OPTIMIZATION
    • PRECLINICAL TESTING
    • INVESTIGATIONAL NEW DRUG APPLICATION AND SAFETY
    • CLINICAL TRIALS
      • Phase I Clinical Trials
      • Phase II Clinical Trials
      • Phase III Clinical Trials
    • NEW DRUG APPLICATION AND APPROVAL
    • MANUFACTURING
    • PHASE IV TRIALS
  • DRUG REPURPOSING
    • LIPINSKI'S RULE OF 5 (RO5) AND EXTENSIONS
    • DEVELOPMENT OF REPURPOSED DRUGS
      • TABLE 3 DIFFERENCES IN NOVEL DRUG DEVELOPMENT AND DRUG REPURPOSING
  • DRUG REPURPOSING METHODS
    • DRUG/TARGET-BASED
    • DISEASE-BASED
  • APPLICATION AREAS OF DRUG REPURPOSING
  • ADVANTAGES AND LIMITATIONS OF DRUG REPURPOSING
    • ADVANTAGES
      • Safety
      • Time and Cost-Effectiveness
      • High Market and Return Potential
      • Treatment of Rare Diseases
    • LIMITATIONS
      • Dependence on Public Data
      • Lack of Funding Opportunities
      • Lack of Familiarity with Regulatory Procedures
    • COMMON REPOSITIONED DRUGS
      • TABLE 4 COMMON REPOSITIONED DRUGS THAT ARE MARKET APPROVED OR UNDERGOING RESEARCH

CHAPTER 4 - REGULATORY ASPECTS

  • TABLE 5 MARKET APPROVALS OF REPURPOSED DRUGS, 2010 TO APRIL 2015
  • RECALLS
    • TABLE 6 RECALLS OF REPURPOSED DRUGS, 2010 TO APRIL 2015
  • SAFETY ALERTS
    • TABLE 7 SAFETY ALERTS FOR REPURPOSED DRUGS

CHAPTER 5 - TRENDS

  • DRUG REPOSITIONING IN PIPELINE
  • MERGERS AND ACQUISITIONS
    • TABLE 8 MERGERS AND ACQUISITIONS OF MAJOR PHARMACEUTICAL COMPANIES, 2010 TO APRIL 2015
  • CURRENT SITUATION
  • FACTORS AFFECTING DRUG REPURPOSING
    • DRIVERS OF THE MARKET FOR DRUG REPURPOSING
      • Aging Population
      • Increased Prevalence of Chronic Diseases
      • Lifestyle Changes
      • Safety
      • Time and Economic Benefits
      • Advances in Drug Repurposing Methods
      • Treatment of Rare Diseases
    • RESTRAINTS AND CHALLENGES
      • Dependence on Public Data
      • Funding Opportunities
      • Lack of Understanding of Regulatory Issues
  • MARKET OPPORTUNITIES

CHAPTER 6 - MARKET ANALYSIS

  • INTRODUCTION
  • MARKET BY REGION
    • MARKET REVENUE
      • TABLE 9 GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 1 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION, 2013-2020 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 10 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%)
      • FIGURE 2 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%)
  • MARKET BY APPLICATION
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 11 GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 3 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION, 2013-2020 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 12 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION, 2014 (%)
      • FIGURE 4 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION, 2014 (%)
    • CENTRAL NERVOUS SYSTEM DISORDERS
      • TABLE 13 TYPES OF CENTRAL NERVOUS SYSTEM DISORDERS
      • Market Overview
      • Market Revenue
        • TABLE 14 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CENTRAL NERVOUS SYSTEM DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 5 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR CENTRAL NERVOUS SYSTEM DISORDERS BY REGION, 2013-2020 ($ MILLIONS)
    • CARDIOVASCULAR DISORDERS
      • TABLE 15 TYPES OF CARDIOVASCULAR DISORDERS
      • Market Overview
      • Market Revenue
        • TABLE 16 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CARDIOVASCULAR DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 6 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR CARDIOVASCULAR DISORDERS BY REGION, 2013-2020 ($ MILLIONS)
    • ONCOLOGY DISORDERS
      • TABLE 17 TYPES OF CANCER-DEPENDING ON THE TISSUE OF ORIGIN
      • Market Overview
      • Market Revenue
        • TABLE 18 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR ONCOLOGY DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 7 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR ONCOLOGY DISORDERS BY REGION 2013-2020 ($ MILLIONS)
    • AUTOIMMUNE DISORDERS
      • TABLE 19 TYPES OF AUTOIMMUNE DISEASES
      • Market Overview
      • Market Revenue
        • TABLE 20 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR AUTOIMMUNE DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 8 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR AUTOIMMUNE DISORDERS BY REGION, 2013-2020 ($ MILLIONS)
  • METABOLIC AND OTHER DISORDERS
    • Diabetes
      • Type 1 Diabetes
      • Type 2 Diabetes
      • Gestational Diabetes
    • Osteoporosis
    • Erectile Dysfunction
    • Benign Prostatic Hyperplasia (BPH)
    • Mediterranean Fever
    • Hemolytic Uremia Syndrome
    • Market Overview
    • Market Revenue
      • TABLE 21 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND OTHER DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 9 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND OTHER DISORDERS BY REGION, 2013-2020 ($ MILLIONS)
  • MARKET ANALYSIS BY USAGE
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 22 GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 10 GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, 2013-2020 ($ MILLIONS)
  • MARKET ANALYSIS BY APPLICATION SITE
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 23 GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION SITE THROUGH 2020 ($ MILLIONS)
      • FIGURE 11 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION SITE 2013-2020 ($ MILLIONS)

CHAPTER 7 - INDUSTRY STRUCTURE

  • CENTRAL NERVOUS SYSTEM DISORDERS
    • MARKET LEADERS
      • TABLE 24 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014
    • MARKET SHARE
      • TABLE 25 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014 (%)
      • FIGURE 12 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014 (%)
  • AUTOIMMUNE DISORDERS
    • MARKET LEADERS
      • TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014
    • MARKET SHARE
      • TABLE 27 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%)
      • FIGURE 13 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%)
  • ONCOLOGY DISORDERS
    • MARKET LEADERS
      • TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY DISORDERS, 2014
    • MARKET SHARE
      • TABLE 29 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY, 2014
      • FIGURE 14 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY, 2014 (%)
  • CARDIOVASCULAR DISORDERS
    • MARKET LEADERS
      • TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014
    • MARKET SHARE
      • TABLE 31 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014
      • FIGURE 15 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014 (%)
  • METABOLIC DISORDERS
    • MARKET LEADERS
      • TABLE 32 LEADING MANUFACTURES/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014
    • MARKET SHARE
      • TABLE 33 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014
      • FIGURE 16 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014 (%)
  • OTHER DISORDERS
    • MARKET LEADERS
      • TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014
    • MARKET SHARE
      • TABLE 35 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014
      • FIGURE 17 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014 (%)

CHAPTER 8 - PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 36 NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015
    • FIGURE 18 NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015
  • PATENTS BY COMPANY
    • TABLE 37 NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015
    • FIGURE 19 NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015
  • PATENTS BY COUNTRY
    • TABLE 38 NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015
    • FIGURE 20 NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015
    • TABLE 39 PATENTS BY COUNTRY, 2010 TO APRIL 2015 (NO/%)
    • FIGURE 21 PATENT SHARES BY COUNTRY, 2010 TO APRIL 2015 (%)
  • PATENTS BY ASSIGNEE
    • TABLE 40 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015
    • FIGURE 22 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015 (NO. OF PATENTS)

CHAPTER 9 - COMPANY PROFILES

  • ABBVIE INC.
  • ACTAVIS INC.
  • ALEXION PHARMACEUTICALS INC.
  • APOTEX INC.
  • AUROBINDO PHARMA LTD.
  • BIOGEN IDEC INC.
  • BIOVISTA INC.
  • CELGENE CORP.
  • DR. REDDY'S LABORATORIES LTD.
  • ELI LILLY & CO.
  • GLAXOSMITHKLINE
  • HOFFMANN-LA ROCHE AG
  • HOSPIRA INC.
  • JENKEN BIOSCIENCES INC.
  • JOHNSON & JOHNSON
  • MELIOR PHARMACEUTICALS INC
  • MERCK & CO. INC.
  • MYLAN PHARMACEUTICALS INC.
  • NOVARTIS AG
  • PAR PHARMACEUTICAL INC.
  • PFIZER INC.
  • SANDOZ
  • SANOFI
  • SOM BIOTECH SL
  • SOSEI GROUP LTD.
  • TAKEDA PHARMACEUTICALS U.S.A. INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • UCB
  • ZYDUS CADILA GROUP

CHAPTER 10 - APPENDIX I: ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: COMPARISON OF CHEMICALLY SYNTHESIZED DRUGS AND BIOLOGIC DRUGS
    • TABLE 2: EVOLUTION OF DRUG PRODUCTS
    • TABLE 3: DIFFERENCES IN NOVEL DRUG DEVELOPMENT AND DRUG REPURPOSING
    • TABLE 4: COMMON REPOSITIONED DRUGS THAT ARE MARKET APPROVED OR UNDERGOING RESEARCH
    • TABLE 5: MARKET APPROVALS OF REPURPOSED DRUGS, 2010 TO APRIL 2015
    • TABLE 6: RECALLS OF REPURPOSED DRUGS, 2010 TO APRIL 2015
    • TABLE 7: SAFETY ALERTS FOR REPURPOSED DRUGS
    • TABLE 8: MERGERS AND ACQUISITIONS OF MAJOR PHARMACEUTICAL COMPANIES, 2010 TO APRIL 2015
    • TABLE 9: GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 10: GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%)
    • TABLE 11: GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 12: GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION, 2014 (%)
    • TABLE 13: TYPES OF CENTRAL NERVOUS SYSTEM DISORDERS
    • TABLE 14: GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CENTRAL NERVOUS SYSTEM DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 15: TYPES OF CARDIOVASCULAR DISORDERS
    • TABLE 16: GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CARDIOVASCULAR DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 17: TYPES OF CANCER-DEPENDING ON THE TISSUE OF ORIGIN
    • TABLE 18: GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR ONCOLOGY DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 19: TYPES OF AUTOIMMUNE DISEASES
    • TABLE 20: GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR AUTOIMMUNE DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 21: GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND OTHER DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 22: GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, THROUGH 2020 ($ MILLIONS)
    • TABLE 23: GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION SITE THROUGH 2020 ($ MILLIONS)
    • TABLE 24: LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014
    • TABLE 25: MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014 (%)
    • TABLE 26: LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014
    • TABLE 27: MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%)
    • TABLE 28: LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY DISORDERS, 2014
    • TABLE 29: MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY, 2014
    • TABLE 30: LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014
    • TABLE 31: MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014
    • TABLE 32: LEADING MANUFACTURES/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014
    • TABLE 33: MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014
    • TABLE 34: LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014
    • TABLE 35: MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014
    • TABLE 36: NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015
    • TABLE 37: NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015
    • TABLE 38: NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015
    • TABLE 39: PATENTS BY COUNTRY, 2010 TO APRIL 2015 (NO/%)
    • TABLE 40: NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 1: GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 2: GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%)
    • FIGURE 3: GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION, 2013-2020 ($ MILLIONS)
    • FIGURE 4: GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION, 2014 (%)
    • FIGURE 5: GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR CENTRAL NERVOUS SYSTEM DISORDERS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 6: GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR CARDIOVASCULAR DISORDERS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 7: GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR ONCOLOGY DISORDERS BY REGION 2013-2020 ($ MILLIONS)
    • FIGURE 8: GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR AUTOIMMUNE DISORDERS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 9: GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND OTHER DISORDERS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 10: GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, 2013-2020 ($ MILLIONS)
    • FIGURE 11: GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION SITE 2013-2020 ($ MILLIONS)
    • FIGURE 12: MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014 (%)
    • FIGURE 13: MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%)
    • FIGURE 14: MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY, 2014 (%)
    • FIGURE 15: MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014 (%)
    • FIGURE 16: MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014 (%)
    • FIGURE 17: MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014 (%)
    • FIGURE 18: NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015
    • FIGURE 19: NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015
    • FIGURE 20: NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015
    • FIGURE 21: PATENT SHARES BY COUNTRY, 2010 TO APRIL 2015 (%)
    • FIGURE 22: NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015 (NO. OF PATENTS)
Back to Top